Back to results
US 12,239,705 B2Granted
Therapeutic mitigation of epithelial infection
AssigneeUniversity of Rochester
InventorsMatthew G. Brewer, Lisa A. Beck, Brian M. Ward, Benjamin L. Miller
Life of this patent
Estimating the term…
Abstract
This invention relates to dermatology and to treatments of infectious skin disease.
Claims17
A method of preventing skin viral infection in a subject in need thereof, the method comprising administering an effective amount of a Janus kinase (JAK) inhibitor and a Th2 pathway antagonist to the subject,
- wherein the JAK inhibitor is selected from the group consisting of pyridone 6, abrocitinib, and ruxolitinib, and
- wherein the Th2 pathway antagonist is an antibody selected from the group consisting of dupilumab, tralokinumab, lebrikizumab, nemolizumab, etokimab, tezepelumab, mepolizumab, reslizumab, and benralizumab.
A pharmaceutical composition or a kit for preventing skin viral infection in a subject, comprising a Janus kinase (JAK) inhibitor and a Th2 pathway antagonist,
- wherein the JAK inhibitor is selected from the group consisting of pyridone 6, abrocitinib, and ruxolitinib, and
- wherein the Th2 pathway antagonist is an antibody selected from the group consisting of dupilumab, tralokinumab, lebrikizumab, nemolizumab, etokimab, tezepelumab, mepolizumab, reslizumab, and benralizumab.
Dependencies are inferred from the claim text.